Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells

Translational Research

Volumn 151, Issue 1, 2008, Pages 36-44

  Roth, Susanne ^a,b   Langguth, Peter ^b   Spicher, Karsten ^a   Enzmann, Harald ^a  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; IRON COMPLEX; IRON DEXTRAN; NANOPARTICLE;

ANIMAL CELL; ANIMAL TISSUE; BIOACCUMULATION; CELL LEVEL; CELL STRAIN HEPG2; CELLULAR DISTRIBUTION; COMPARATIVE TOXICOLOGY; CONTROLLED STUDY; EGG; EMBRYO; EMBRYOTOXICITY; FETUS WEIGHT; HUMAN; HUMAN CELL; IRON OVERLOAD; IRON TRANSPORT; KIDNEY PARENCHYMA; LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL; TISSUE DISTRIBUTION; TOXICOKINETICS; TURKEY (BIRD);

EID: 36448948292     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2007.09.001     Document Type: Review

References (25)

1. Chertow G.M., Mason P.D., Vaage-Nilsen O., and Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 19 (2004) 1571-1575
2. Valderrabano F., Jofre R., and Lopez-Gomez J.M. Quality of life in end-stage renal disease patients. Am J Kidney Dis 38 (2001) 443-464
3. Besarab A., Amin N., Ahsan M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 (2000) 530-538
4. Lappin T.R., Maxwell A.P., and Johnston P.G. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist 12 (2007) 362-365
5. Henry D.H. The role of intravenous iron in cancer-related anemia. Oncology 20 8 suppl 6 (2006) 21-24
6. Shah S.V., and Alam M.G. Role of iron in atherosclerosis. Am J Kidney Dis 41 3 suppl 1 (2003) S80-S83
7. Macdougall I.C. Strategies for iron supplementation: oral versus intravenous. Kidney Int 69 suppl (1999) S61-S66
8. Afzali B., and Goldsmith D.J. Intravenous iron therapy in renal failure: friend and foe?. J Nephrol 17 (2004) 487-495
9. Kunzi-Rapp K., Genze F., Kufer R., Reich E., Hautmann R.E., and Gschwend J.E. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J Urol 166 (2001) 1502-1507
10. Rebouche C.J., Wilcox C.L., and Widness J.A. Microanalysis of non-heme iron in animal tissues. J Biochem Biophys Methods 58 (2004) 239-251
11. Smith P.K., Krohn R.I., Hermanson G.T., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 150 (1985) 76-85
12. Agarwal R., Rizkala A.R., Bastani B., Kaskas M.O., Leehey D.J., and Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26 (2006) 445-454
13. Sengolge G., Horl W.H., and Sunder-Plassmann G. Intravenous iron therapy: well-tolerated, yet not harmless. Eur J Clin Invest 35 suppl 3 (2005) 46-51
14. Horl W.H. Iron therapy for renal anemia: how much needed, how much harmful?. Pediatr Nephrol 22 (2007) 480-489
15. Zager R.A., Johnson A.C., Hanson S.Y., and Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40 (2002) 90-103
16. Zager R.A., Johnson A.C., and Hanson S.Y. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 66 (2004) 144-156
17. Boettcher-Buehler E, Gethins M. Safety and tolerability of parenteral iron formulations. Fe Report, XXXIX Congress of the European Renal Association (ERA)-European Dialysis and Transplant Association (EDTA), Copenhagen, 2002.
18. Jahn M., Roth S., and Langguth P. Parenterale kolloidale Eisenkomplexpräparate. Deutsche Apotheker Zeitung 146 (2006) 15110-15119
19. Kudasheva D.S., Lai J., Ulman A., and Cowman M.K. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem 98 (2004) 1757-1769
20. Van Wyck D., Anderson J., and Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19 (2004) 561-565
21. Agarwal R. Transferrin saturation with intravenous irons: an in vitro study. Kidney Int 66 (2004) 1139-1144
22. Torrance J.D., and Bothwell T.H. Tissue iron stores. In: Cook J.D. (Ed). Iron. Methods in hematology. 1st ed. (1980), Churchill Livingstone, New York 90-115
23. Scheiber-Mojdehkar B., Sturm B., Plank L., Kryzer I., and Goldenberg H. Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 65 (2003) 1973-1978
24. Rose C., Vandevenne P., Bourgeois E., Cambier N., and Ernst O. Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. Eur J Haematol 77 (2006) 145-149
25. Hodges Y.K., Weinberger H.D., Stephens J., Horwitz M.A., and Horwitz L.D. Desferri-Exochelin, a lipid-soluble, hexadentate iron chelator, effectively removes tissue iron. Transl Res 148 (2006) 63-71